Literature DB >> 35118459

Contemporary Non-hormonal Therapies for the Management of Vasomotor Symptoms Associated with Menopause: A Literature Review.

Sabrina Sahni1, Angie Lobo-Romero2, Taryn Smith3.   

Abstract

Nearly 75% of all menopausal women experience bothersome vasomotor symptoms including hot flushes and night sweats. Yet vasomotor symptoms continue to be an undertreated and underdiagnosed symptom of menopause which can negatively affect a woman's overall quality of life. While hormone therapy has been widely utilized to ameliorate hot flushes, not all women are candidates for use, especially those with increased risk of cardiovascular disease, thromboembolic disease, and/or women at an increased risk of certain hormone-dependent cancers. The current literature provides strong evidence for non-hormonal therapies in women who experience vasomotor symptoms. This article reviews the evidence for the use of non-hormonal pharmacologic therapies for the treatment of menopausal symptoms including antidepressants, gabapentinoids, clonidine and anticholinergics. We also review data on emerging therapies including the latest evidence on neurokinin-1 and -3 antagonists. These therapies should be considered when hormonal options are contraindicated and/or not preferred by the patient. While there are many options available, clinicians should individualize therapy based on the patient's needs and goals while mitigating bothersome side effects. © Touch Medical Media 2021.

Entities:  

Keywords:  Vasomotor symptoms; hormone therapy; hot flushes; menopause; non-hormonal therapy

Year:  2021        PMID: 35118459      PMCID: PMC8676100          DOI: 10.17925/EE.2021.17.2.133

Source DB:  PubMed          Journal:  touchREV Endocrinol        ISSN: 2752-5457


  51 in total

1.  Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial.

Authors:  Herman Depypere; Dirk Timmerman; Gilbert Donders; Peter Sieprath; Steven Ramael; Jean Combalbert; Hamid R Hoveyda; Graeme L Fraser
Journal:  J Clin Endocrinol Metab       Date:  2019-12-01       Impact factor: 5.958

2.  Managing vasomotor symptoms in women after cancer.

Authors:  J V Pinkerton; R J Santen
Journal:  Climacteric       Date:  2019-05-13       Impact factor: 3.005

3.  Phase III evaluation of fluoxetine for treatment of hot flashes.

Authors:  Charles L Loprinzi; Jeff A Sloan; Edith A Perez; Susan K Quella; Phillip J Stella; James A Mailliard; Michele Y Halyard; Sandhya Pruthi; Paul J Novotny; Teresa A Rummans
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

4.  Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial.

Authors:  Thomas Guttuso; Roger Kurlan; Michael P McDermott; Karl Kieburtz
Journal:  Obstet Gynecol       Date:  2003-02       Impact factor: 7.661

Review 5.  Use of gabapentin in patients experiencing hot flashes.

Authors:  Jamie N Brown; Betsy R Wright
Journal:  Pharmacotherapy       Date:  2009-01       Impact factor: 4.705

6.  Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial.

Authors:  Ellen W Freeman; Katherine A Guthrie; Bette Caan; Barbara Sternfeld; Lee S Cohen; Hadine Joffe; Janet S Carpenter; Garnet L Anderson; Joseph C Larson; Kristine E Ensrud; Susan D Reed; Katherine M Newton; Sheryl Sherman; Mary D Sammel; Andrea Z LaCroix
Journal:  JAMA       Date:  2011-01-19       Impact factor: 157.335

7.  A randomised controlled trial of a cognitive behavioural intervention for women who have menopausal symptoms following breast cancer treatment (MENOS 1): trial protocol.

Authors:  Eleanor Mann; Melanie Smith; Jennifer Hellier; Myra S Hunter
Journal:  BMC Cancer       Date:  2011-01-31       Impact factor: 4.430

8.  Low-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopause.

Authors:  JoAnn V Pinkerton; Hadine Joffe; Kazem Kazempour; Hana Mekonnen; Sailaja Bhaskar; Joel Lippman
Journal:  Menopause       Date:  2015-01       Impact factor: 2.953

9.  Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial.

Authors:  Julia K Prague; Rachel E Roberts; Alexander N Comninos; Sophie Clarke; Channa N Jayasena; Zachary Nash; Chedie Doyle; Deborah A Papadopoulou; Stephen R Bloom; Pharis Mohideen; Nicholas Panay; Myra S Hunter; Johannes D Veldhuis; Lorraine C Webber; Les Huson; Waljit S Dhillo
Journal:  Lancet       Date:  2017-04-03       Impact factor: 79.321

10.  Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause.

Authors:  David J Portman; Andrew M Kaunitz; Kazem Kazempour; Hana Mekonnen; Sailaja Bhaskar; Joel Lippman
Journal:  Menopause       Date:  2014-10       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.